Additional file 1 of Risk-based lung cancer screening in heavy smokers: a benefit–harm and cost-effectiveness modeling study
Creators: name: Liu, Yin
name: Xu, Huifang
name: Lv, Lihong
name: Wang, Xiaoyang
name: Kang, Ruihua
name: Guo, Xiaoli
name: Wang, Hong
name: Zheng, Liyang
name: Liu, Hongwei
name: Guo, Lanwei
name: Chen, Qiong
name: Liu, Shuzheng
name: Qiao, Youlin
name: Zhang, Shaokai
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Biotechnology
subject: Environmental Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Science Policy

description: Additional file 1: Table S1. Risk-factors considered in the relative risk model for lung cancer. Table S2. Estimated incidence of lung cancer and mortality rates of non-lung cancer by sex and age (1/10^5). Table S3. Details of the evaluated LDCT screening strategies. Table S4. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Sensitivity of LDCT: 0.890). Table S5. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Sensitivity of LDCT: 1.000). Table S6. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Specificity of LDCT: 0.700). Table S7. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Specificity of LDCT: 0.930). Table S8. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (overdiagnosis rate when screening: 0.0155). Table S9. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (overdiagnosis rate when screening: 0.0465). Table S10. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Excess relative risk of LC per screening: 0.0003). Table S11. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Excess relative risk of LC per screening: 0.0019). Table S12. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Biopsy diagnosis cost: decreased by 50%). Table S13. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Biopsy diagnosis cost: increased by 50%). Table S14. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (LDCT test cost: decreased by 50%). Table S15. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (LDCT test cost: increased by 50%). Table S16. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Background medical treatment costs: decreased by 50%). Table S17. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Background medical treatment costs: increased by 50%). Table S18. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Disutility associated with a false positive screen: decreased by 50%). Table S19. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Disutility associated with a false positive screen: increased by 50%). Table S20. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Adherence: decreased by 50%). Table S21. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (No discount). Table S22. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Discount: 8%). Table S23. Cost-effectiveness estimates for lung cancer screening scenarios ordered by QALYs (Quit smoking with being screened). Fig. S1. Cost-effectiveness acceptability curves of H1-MH3-LMnone-Lnone vs No screening. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S2. Cost-effectiveness acceptability curves of H1-MH2-LMnone-Lnone vs H1-MH3-LMnone-Lnone. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S3. Cost-effectiveness acceptability curves of H1-MH3-LM3-L3 vs H1-MH2-LMnone-Lnone. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S4. Cost-effectiveness acceptability curves of H1-MH2-LM3-L3 vs H1-MH3-LM3-L3. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S5. Cost-effectiveness acceptability curves of H1-MH2-LM2-L2 vs H1-MH2-LM3-L3. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S6. Cost-effectiveness acceptability curves of H1-MH1-LM2-L2 vs H1-MH2-LM2-L2. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S7. Cost-effectiveness acceptability curves of H1-MHone-off-LMone-off-Lone-off vs No screening if individuals quit smoking with being screened. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S8. Cost-effectiveness acceptability curves of H1-MH3-LMone-off-Lone-off vs H1-MHone-off-LMone-off-Lone-off if individuals quit smoking with being screened. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S9. Cost-effectiveness acceptability curves of H1-MH3-LM3-L3 vs H1-MH3-LMone-off-Lone-off if individuals quit smoking with being screened. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S10. Cost-effectiveness acceptability curves of H1-MH2-LM3-L3 vs H1-MH3-LM3-L3 if individuals quit smoking with being screened. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S11. Cost-effectiveness acceptability curves of H1-MH1-LM3-L3 vs H1-MH2-LM3-L3 if individuals quit smoking with being screened. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S12. Cost-effectiveness acceptability curves of H1-MH2-LM2-L2 vs H1-MH1-LM3-L3 if individuals quit smoking with being screened. QALY, quality-adjusted life year; GDP, gross domestic product. Fig. S13. Cost-effectiveness acceptability curves of H1-MH1-LM2-L2 vs H1-MH2-LM2-L2 if individuals quit smoking with being screened. QALY, quality-adjusted life year; GDP, gross domestic product.